Loading…
Loading…
Just given the really strong launch of JASCAYD by BI, does this impact the bar for success in your view?
do you see these as agents that maybe you know, appeal more to community providers
can you remind us why you opted not to enrich in the SSP trial for atherosclerosis
I'm wondering if you think these 2 areas, psych and vaccines are areas that Lilly can scale?
How do you guys think about the opportunity for injectable PCSK9 switch versus the bulk of the opportunity
does this provide any concerning read-through to some of the ongoing readouts for LITESPARK-022 and the ability to see OS benefit there
how you're thinking about the value add of the GLP-one amylin injectable combination relative to the monotherapy
as I look at the back half of the year, sort of an implied low single-digit growth
can you discuss your specialty sales force strategy? And what percent of the market are you -- do you think you'll be able to access
your EBITDA goes up about $150 million or so. It looks like that is largely on the cost restructuring dynamics, but you have +$400 million in revenue
in a scenario where, I guess, the ban isn't lifted, do the price penalties, which I think were $100 million, did they recur in that scenario
just on the enterprise review and just why not an update today versus giving the update on 1Q '26
I know this isn't like a new product issue, but like is generic Symbicort a headwind in 2025, due to competition
why does the Indore facility issues have an impact on revenues outside the United States